176755-83-2

Upstream product

• 117032-49-2 4-(1,2,4-triazol-1-yl)-5'-O-(4,4'-dimethoxytriphenylmethyl)-3'-O-trimethylsilyl thymidine 
• 288-36-8 1,2,3-triazole 
• 126144-60-3 3'-O-trimethylsilyl-5'-O-dimethoxytrityl-thymidine 
• 40615-39-2 5'-O-(4-4'-dimethoxytrityl)thymidine 
• 10025-87-3 trichlorophosphate 
• 7664-41-7 ammonia 
• 7732-18-5 water 
• 288-88-0 1,2,4-Triazole 
• 75-77-4 chloro-trimethyl-silane 
• 50-89-5 thymidine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 

Downstream Products

• 838-07-3 5-methyldeoxycytidine 
• 847699-97-2 benzoic acid 5-(4-benzoylamino-5-methyl-2-oxo-2H-pyrimidin-1-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-yl ester 
• 176755-84-3 N-(1-{(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-5-methyl-2-oxo-1,2-dihydro-pyrimidin-4-yl)-isobutyramide 
• 104579-03-5 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidine 
• 105931-57-5 5-methyl dC amidite 

Relevant academic research and scientific papers

Efficient large-scale synthesis of 5′-O-dimethoxytrityl-N 4-benzoyl-5-methyl-2′-deoxycytidine

An efficient process to synthesize 5′- O -dimethoxytrityl-N 4 -benzoyl-5-methyl-2 ′-deoxycytidine in high yield and quality is described. Final benzoylation was improved by developing a method to selectively hydrolyze benzoyl ester impurities. This inexpensive approach was scaled up to multi-kilogram quantities for routine use in oligonucleotide therapeutics. Copyright Taylor & Francis Group, LLC.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Modulation of DC-SIGN expression

Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.

Antisense modulation of phospholipase D2 expression

Antisense compounds, compositions and methods are provided for modulating the expression of phospholipase D2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phospholipase D2. Methods of using these compounds for modulation of phospholipase D2 expression and for treatment of diseases associated with expression of phospholipase D2 are provided.

Antisense modulation of DEXRAS1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of DEXRAS1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding DEXRAS1. Methods of using these compounds for modulation of DEXRAS1 expression and for treatment of diseases associated with expression of DEXRAS1 are provided.

Antisense modulation of fatty acid synthase expression

Antisense compounds, compositions and methods are provided for modulating the expression of fatty acid synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fatty acid synthase. Methods of using these compounds for modulation of fatty acid synthase expression and for treatment of diseases associated with expression of fatty acid synthase are provided.

Modulation of forkhead box O1A expression

Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Antisense modulation of perilipin expression

Antisense compounds, compositions and methods are provided for modulating the expression of perilipin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding perilipin. Methods of using these compounds for modulation of perilipin expression and for treatment of diseases associated with expression of perilipin are provided.

Antisense modulation of EDG5 expression

Antisense compounds, compositions and methods are provided for modulating the expression of EDG5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG5. Methods of using these compounds for modulation of EDG5 expression and for treatment of diseases associated with expression of EDG5 are provided.